Stockscreener 앱 받기
61.35
3.02%
1.80
전일 마감가:
$59.55
열려 있는:
$60.985
하루 거래량:
10.57M
Relative Volume:
2.32
시가총액:
$23.67B
수익:
$4.66B
순이익/손실:
$836.30M
주가수익비율:
29.31
EPS:
2.093
순현금흐름:
$1.08B
1주 성능:
-0.36%
1개월 성능:
-1.64%
6개월 성능:
+5.38%
1년 성능:
-12.68%
1일 변동 폭
$59.70
$62.85
1주일 범위
$56.72
$62.85
52주 변동 폭
$54.11
$89.98
덱스컴 Stock (DXCM) Company Profile
명칭
Dexcom Inc
전화
(858) 200-0200
주소
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
61.35 | 23.67B | 4.66B | 836.30M | 1.08B | 2.093 |
ABT
Abbott Laboratories
|
89.46 | 155.82B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
294.73 | 112.88B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
80.00 | 102.71B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
56.50 | 83.97B | 20.62B | 3.56B | 3.66B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.98 | 48.42B | 6.30B | 1.07B | 1.34B | 1.8406 |
덱스컴 Stock (DXCM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2026-01-12 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 개시 | Evercore ISI | In-line |
| 2025-10-21 | 재개 | Stifel | Buy |
| 2025-09-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 개시 | Argus | Buy |
| 2025-06-16 | 개시 | Truist | Buy |
| 2025-05-30 | 개시 | Goldman | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-03 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 개시 | Redburn Atlantic | Neutral |
| 2024-03-12 | 개시 | RBC Capital Mkts | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-04-17 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 개시 | UBS | Buy |
| 2023-01-26 | 개시 | Wolfe Research | Outperform |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-15 | 개시 | Bernstein | Outperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-01-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-28 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2021-01-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-10-02 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 재확인 | Piper Sandler | Overweight |
| 2020-05-14 | 개시 | Wells Fargo | Equal Weight |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-11-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-10-23 | 개시 | Stifel | Buy |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-19 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-09-12 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 재확인 | Canaccord Genuity | Buy |
| 2018-07-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
| 2018-05-03 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-04 | 개시 | Goldman | Sell |
| 2018-04-04 | 개시 | Guggenheim | Neutral |
| 2018-03-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 재확인 | Wedbush | Outperform |
모두보기
덱스컴 주식(DXCM)의 최신 뉴스
Dexcom, Inc. Q1 2026 Financial Results: Strong Revenue, Earnings, and Forward-Looking Statements - Minichart
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DexCom Faces Potential Headwinds in 2026, but Expanding Reimbursement Offers Long-Term Prospects - Morningstar
DexCom Medicare Coverage NCD Remains Biggest 2026 Catalyst, RBC Says - marketscreener.com
JPMorgan Adjusts DexCom Price Target to $65 From $75 - marketscreener.com
DexCom, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:DXCM) 2026-05-01 - Seeking Alpha
DexCom Stock Up on Q1 Earnings & Revenues Beat, Margins Rise - Yahoo Finance
DexCom, Inc. (NASDAQ:DXCM) Q1 2026 Earnings Call Transcript - Insider Monkey
Dexcom reports 15% YoY revenue uptick in Q1 yet maintains prior FY26 outlook - Yahoo Finance
DexCom Inc (NASDAQ:DXCM): A GARP Stock with Affordable Growth and Strong Fundamentals - ChartMill
Barclays Adjusts Price Target on DexCom to $67 From $72, Maintains Underweight Rating - marketscreener.com
Leerink Partners Adjusts Price Target on DexCom to $80 From $95, Maintains Outperform Rating - marketscreener.com
Bernstein Adjusts Price Target on DexCom to $77 From $83, Maintains Outperform Rating - marketscreener.com
Bernstein SocGen lowers DexCom stock price target on valuation By Investing.com - Investing.com Canada
Raymond James Adjusts Price Target on DexCom to $81 From $83, Maintains Strong Buy Rating - marketscreener.com
Canaccord Genuity Adjusts Price Target on DexCom to $100 From $95, Maintains Buy Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on DexCom to $80 From $82, Maintains Buy Rating - marketscreener.com
TD Cowen Adjusts Price Target on DexCom to $75 From $84, Maintains Buy Rating - marketscreener.com
Citigroup Adjusts Price Target on DexCom to $79 From $84, Maintains Buy Rating - marketscreener.com
HB Wealth Management LLC Cuts Stake in DexCom, Inc. $DXCM - MarketBeat
BTIG Remains Bullish on DexCom, Inc. (DXCM) - Insider Monkey
DexCom Inc (DXCM) Q1 2026 Earnings Call Highlights: Strong Reven - GuruFocus
DexCom Inc (DXCM) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Market Expansions - GuruFocus
DexCom Inc (DXCM) Stock Price, Trades & News - GuruFocus
DexCom Q1 2026 slides: margin expansion accelerates, guidance raised By Investing.com - Investing.com South Africa
DexCom (DXCM) Reports Strong Q1 2026 Revenue Growth Driven by Pr - GuruFocus
Is It Too Late to Buy DexCom Inc (DXCM) After 3.5% Rally? GF Val - GuruFocus
Is DexCom (DXCM) 45.7% Undervalued After Q1 2026 Earnings Beat? - GuruFocus
DexCom (DXCM) Q1 2026 Earnings Transcript - The Motley Fool
DexCom Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: DexCom beats Q1 2026 forecasts, stock rises - Investing.com
Transcript : DexCom, Inc., Q1 2026 Earnings Call, Apr 30, 2026 - marketscreener.com
DexCom Q1 2026 Earnings Call Transcript - Benzinga
DexCom, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
DexCom (DXCM) Q1 Earnings and Revenues Top Estimates - Yahoo Finance Singapore
Dexcom reaffirms full-year forecast after topping quarterly estimates - marketscreener.com
Dexcom shares fell as it reaffirms full-year outlook By Investing.com - Investing.com Canada
DexCom (NASDAQ:DXCM) Beats Q1 Earnings Forecasts, But Guidance and Revenue Miss Fuel After-Hours Drop - ChartMill
Dexcom falls over 5% despite better-than-expected Q1 print, as revenue guidance disappoints - Investing.com India
Q1 2026 Dexcom Inc Earnings Call Transcript - GuruFocus
DexCom Q1 Adjusted Earnings, Revenue Rise - marketscreener.com
DexCom (NASDAQ:DXCM) Exceeds Q1 CY2026 Expectations But Stock Drops - Yahoo Finance
Earnings Flash (DXCM) DexCom, Inc. Reports Q1 Revenue $1.19B, vs. FactSet Est of $1.17B - marketscreener.com
Earnings Flash (DXCM) DexCom, Inc. Posts Q1 Adjusted EPS $0.56 per Share, vs. FactSet Est of $0.47 - marketscreener.com
DexCom: Q1 Earnings Snapshot - marketscreener.com
[8-K] DEXCOM INC Reports Material Event - Stock Titan
Dexcom Reports First Quarter 2026 Financial Results - Business Wire
DexCom earnings ahead: Can margin gains offset growth concerns? By Investing.com - Investing.com India
DexCom earnings ahead: Can margin gains offset growth concerns? - Investing.com
Jennison Associates LLC Sells 4,300,430 Shares of DexCom, Inc. $DXCM - MarketBeat
Dexcom Inc. Stock (US2521311074): Q1 2026 Earnings Release Scheduled for April 30 - AD HOC NEWS
덱스컴 (DXCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.68%
0.31%
자본화:
|
볼륨(24시간):